CD2 deficiency partially prevents small bowel inflammation and improves parasite in murine Toxoplasma gondii infection

World Journal of Gastroenterology

Volumn 13, Issue 31, 2007, Pages 4207-4213

  Pawlowski, Nina N ^a   Struck, Daniela ^a   Grollich, Katja ^a   Kühl, Anja A ^a   Zeitz, Martin ^a   Liesenfeld, Oliver ^a   Hoffmann, Jörg C ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b St Marienund St Annastiftskrankenhaus   (Germany)

Author keywords

CD2; IL 6; Ileitis; Inflammatory bowel disease; Interferon ; Toxoplasma gondii

Indexed keywords

CD2 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; CYST; CYTOKINE RELEASE; ENTERITIS; ILEITIS; ILEUM; INFECTION CONTROL; INFECTION RESISTANCE; INTERFERON PRODUCTION; INTESTINE NECROSIS; KAPLAN MEIER METHOD; MOUSE; NONHUMAN; PARASITE CONTROL; PARASITE IDENTIFICATION; PARASITE VIRULENCE; PROTEIN DEFICIENCY; RISK REDUCTION; SPLEEN CELL; TOXOPLASMA GONDII; TOXOPLASMOSIS; WEIGHT REDUCTION; WILD TYPE;

EID: 34548472406     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i31.4207     Document Type: Article

References (51)

1. Fuss IJ, Marth T, Neurath MF, Pearlstein GF, Jain A, Strober W. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 1999; 117: 1078-1088
2. Mannon P, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, Dolin B, Goodman N, Groden C, Hornung RL, Quezado M, Yang Z, Neurath MF, Salfeld J, Veldman GM, Schwertschlag U, Strober W. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004; 351: 2069-2079
3. Thompson-Snipes L, Skamene E, Radzioch D. Acquired resistance but not innate resistance to Mycobacterium bovis bacillus Calmette-Guerin is compromised by interleukin-12 ablation. Infect Immun 1998; 66: 5268-5274
4. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 2005; 44: 714-720
5. Kuhl AA, Pawlowski NN, Grollich K, Loddenkemper C, Zeitz M, Hoffmann JC. Aggravation of intestinal inflammation by depletion/ deficiency of gammadelta T cells in different types of IBD animal models. J Leukoc Biol 2007; 81: 168-175
6. Kosiewicz MM, Nast CC, Krishnan A, Rivera-Nieves J, Moskaluk CA, Matsumoto S, Kozaiwa K, Cominelli F. Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease. J Clin Invest 2001; 107: 695-702
7. Suzuki Y, Sher A, Yap G, Park D, Neyer LE, Liesenfeld O, Fort M, Kang H, Gufwoli E. IL-10 is required for prevention of necrosis in the small intestine and mortality in both genetically resistant BALB/c and susceptible C57BL/6 mice following peroral infection with Toxoplasma gondii. J Immunol 2000; 164: 5375-5382
8. Liesenfeld O, Kosek J, Remington JS, Suzuki Y. Association of CD4+ T cell-dependent, interferon-gamma-mediated necrosis of the small intestine with genetic susceptibility of mice to peroral infection with Toxoplasma gondii. J Exp Med 1996; 184: 597-607
9. Liesenfeld O, Kang H, Park D, Nguyen TA, Parkhe CV, Watanabe H, Abo T, Sher A, Remington JS, Suzuki Y. TNF-alpha, nitric oxide and IFN-gamma are all critical for development of necrosis in the small intestine and early mortality in genetically susceptible mice infected perorally with Toxoplasma gondii. Parasite Immunol 1999; 21: 365-376
10. Liesenfeld O. Oral infection of C57BL/6 mice with Toxoplasma gondii: a new model of inflammatory bowel disease? J Infect Dis 2002; 185 Suppl 1: S96-S101
11. Vossenkamper A, Struck D, Alvarado-Esquivel C, Went T, Takeda K, Akira S, Pfeffer K, Alber G, Lochner M, Forster I, Liesenfeld O. Both IL-12 and IL-18 contribute to small intestinal Th1-type immunopathology following oral infection with Toxoplasma gondii, but IL-12 is dominant over IL-18 in parasite control. Eur J Immunol 2004; 34: 3197-3207
12. Lieberman LA, Cardillo F, Owyang AM, Rennick DM, Cua DJ, Kastelein RA, Hunter CA. IL-23 provides a limited mechanism of reilstance to acute toxoplasmosis in the absence of IL-12. J Immunol 2004; 173: 1887-1893
13. Davis SJ, Ikemizu S, Evans EJ, Fugger L, Bakker TR, van der Merwe PA. The nature of molecular recognition by T cells. Nat Immunol 2003; 4: 217-224
14. van der Merwe PA. Formation and function of the immunological synapse. Curr Opin Immunol 2002; 14: 293-298
15. van der Merwe PA, Davis SJ. Molecular interactions mediating T cell antigen recognition. Annu Rev Immunol 2003; 21: 659-684
16. Pirzer UC, Schurmann G, Post S, Betzler M, Meuer SC. Differential responsiveness to CD3-Ti vs. CD2-dependent activation of human intestinal T lymphocytes. Eur J Immunol 1990; 20: 2339-2342
17. Zeitz M, Quinn TC, Graeff AS, James SP. Mucosal T cells provide helper function but do not proliferate when stimulated by specific antigen in lymphogranuloma venereum proctitis in nonhuman primates. Gastroenterology 1988; 94: 353-366
18. Killeen N, Stuart SG, Littman DR. Development and function of T cells in mice with a disrupted CD2 gene. EMBO J 1992; 11: 4329-4336
19. Evans CF, Rall GF, Killeen N, Littman D, Oldstone MB. CD2-deficient mice generate virus-specific cytotoxic T lymphocytes upon infection with lymphocytic choriomeningitis virus. J Immunol 1993; 151: 6259-6264
20. Teh SJ, Killeen N, Tarakhovsky A, Littman DR, Teh HS. CD2 regulates the positive selection and function of antigen-specific CD4- CD8+ T cells. Blood 1997; 89: 1308-1318
21. Beck JM, Blackmon MB, Rose CM, Kimzey SL, Preston AM, Green JM. T cell costimulatory molecule function determines susceptibility to infection with Pneumocystis carinii in mice. J Immunol 2003; 171: 1969-1977
22. Pawlowski NN, Kakirman H, Kuhl AA, Liesenfeld O, Groffich K, Loddenkemper C, Zeitz M, Hoffmann JC. Alpha CD 2 mAb treatment safely attenuates adoptive transfer colitis. Lab Invest 2005; 85: 1013-1023
23. Suzuki Y, Yang Q, Conley FK, Abrams JS, Remington JS. Antibody against interleukin-6 reduces inflammation and numbers of cysts in brains of mice with toxoplasmic encephalitis. Infect Immun 1994; 62: 2773-2778
24. Siegmund B, Fantuzzi G, Rieder F, Gamboni-Robertson F, Lehr HA, Hartmann G, Dinarello CA, Endres S, Eigler A. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal EFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Camp Physiol 2001; 281: R1264-R1273
25. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
26. Heimesaat MM, Bereswill S, Fischer A, Fuchs D, Struck D, Niebergall J, Jahn HK, Dunay IR, Moter A, Gescher DM, Schumann RR, Gobel UB, Liesenfeld O. Gram-negative bacteria aggravate murine small intestinal Th1-type immunopathology following oral infection with Toxoplasma gondii. J Immunol 2006; 177: 8785-8795
27. Conley FK, Jenkins KA, Remington JS. Toxoplasma gondii infection of the central nervous system. Use of the peroxidase-antiperoxidase method to demonstrate toxoplasma in formalin fixed, paraffin embedded tissue sections. Hum Pathol 1981; 12: 690-698
28. Gazzinelli RT, Wysocka M, Hieny S, Scharton-Kersten T, Cheever A, Kuhn R, Muller W, Trinchieri G, Sher A. In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. J Immunol 1996; 157: 798-805
29. Scharton-Kersten TM, Yap G, Magram J, Sher A. Inducible nitric oxide is essential for host control of persistent but not acute infection with the intracellular pathogen Toxoplasma gondii. J Exp Med 1997; 185: 1261-1273
30. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet 2004; 363: 1965-1976
31. Suzuki Y, Conley FK, Remington JS. Importance of endogenous IFN-gamma for prevention of toxoplasmic encephalitis in mice. J Immunol 1989; 143: 2045-2050
32. Suzuki Y, Orellana MA, Schreiber RD, Remington JS. Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science 1988; 240: 516-518
33. Beaman MH, Hunter CA, Remington JS. Enhancement of intracellular replication of Toxoplasma gondii by IL-6. Interactions with IFN-gamma and TNF-alpha. J Immunol 1994; 153: 4583-4587
34. Suzuki Y, Rard S, Liesenfeld O, Kojima T, Lim S, Nguyen TA, Dalrymple SA, Murray R, Remington JS. Impaired resistance to the development of toxoplasmic encephalitis in interleukin-6-deficient mice. Infect Immun 1997; 65: 2339-2345
35. Chardes T, Velge-Roussel F, Mevelec P, Mevelec MN, Buzoni-Gatel D, Bout D. Mucosal and systemic cellular immune responses induced by Toxoplasma gondii antigens in cyst orally infected mice. Immunology 1993; 78: 421-429
36. Heimesaat MM, Fischer A, Jahn HK, Niebergall J, Freudenberg M, Blaut M, Liesenfeld O, Schumann RR, Göbel UB, Bereswill S. Exacerbation of murine ileitis by toll-like receptor 4 mediated sensing of lipopolysaccharide from commensal Escherichia coli. Gut 2007; 56: 941-948
37. Bachmann MF, Barner M, Kopf M. CD2 sets quantitative thresholds in T cell activation. J Exp Med 1999; 190: 1383-1392
38. Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, Schutz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schurmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S, Neurath MF. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 2000; 6: 583-588
39. Yamamoto M, Yoshizaki K, Kishimoto T, Ito H. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 2000; 164: 4878-4882
40. Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, Matsumoto T, Yamamura T, Azuma J, Nishimoto N, Yoshizaki K, Shimoyama T, Kishimoto T. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004; 126: 989-996; discussion 947
41. Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, Kleinschek MA, Owyang A, Mattson J, Blumenschein W, Murphy E, Sathe M, Cua DJ, Kastelein RA, Rennick D. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006; 116: 1310-1316
42. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6: 1123-1132
43. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006; 24: 677-688
44. Hirota K, Hashimoto M, Yoshitomi H, Tanaka S, Nomura T, Yamaguchi T, Iwakura Y, Sakaguchi N, Sakaguchi S. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med 2007; 204: 41-47
45. Tozawa K, Hanai H, Sugimoto K, Baba S, Sugimura H, Aoshi T, Uchijima M, Nagata T, Koide Y. Evidence for the critical role of interleukin-12 but not interferon-gamma in the pathogenesis of experimental colitis in mice. J Gastroenterol Hepatol 2003; 18: 578-587
46. Camoglio L, te Velde AA, de Boer A, ten Kate FJ, Kopf M, van Deventer SJ. Hapten-induced colitis associated with maintained Th1 and inflammatory responses in IFN-gamma receptor-deficient mice. Eur J Immunol 2000; 30: 1486-1495
47. Davidson NJ, Hudak SA, Lesley RE, Menon S, Leach MW, Rennick DM. IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. Immunol 1998; 161: 3143-3149
48. Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994; 1: 553-562
49. Sasada T, Yang H, Reinherz EL. CD2 facilitates differentiation of CD4 Th cells without affecting Th1/Th2 polarization. J Immunol 2002; 168: 1113-1122
50. van Der Merwe PA, Davis SJ. Immunology. The immunological synapse--a multitasking system. Science 2002; 295: 1479-1480
51. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-1104